← Patent-cliff monitor small molecule VANRAFIA ATRASENTAN HYDROCHLORIDE
Loss of exclusivity March 2043 latest FDA-listed patent expiry
Company Novartis → See this company's full patent-cliff portfolio Drug detail Brand name VANRAFIA Active ingredient ATRASENTAN HYDROCHLORIDE Strength EQ 0.75MG BASE Dosage form TABLET Route ORAL Modality Small molecule FDA approval April 2025 Marketing status RX
Listed patents Patent Expires Type 12582631 March 2043 use U-3980 12521369 March 2041 use U-3980 11491137 December 2040 use U-3980 12370174 December 2040 use U-3980 12121509 December 2040 use U-3980 11998526 December 2040 use U-3980 10016393 July 2034 product 9364458 July 2034 product 11874283 February 2032 use U-3980 8623819 August 2028 use U-3980
Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.